Holen Sie sich die Stockscreener-App
6.40
0.16%
-0.010
Handel nachbörslich:
6.30
-0.10
-1.56%
Schlusskurs vom Vortag:
$6.41
Offen:
$6.47
24-Stunden-Volumen:
459.47K
Relative Volume:
0.81
Marktkapitalisierung:
$348.29M
Einnahmen:
$3.32M
Nettoeinkommen (Verlust:
$-156.76M
KGV:
-2.2055
EPS:
-2.9019
Netto-Cashflow:
$-140.13M
1W Leistung:
-8.31%
1M Leistung:
-5.19%
6M Leistung:
-80.31%
1J Leistung:
-53.04%
1-Tages-Spanne:
$6.26
$6.60
1-Wochen-Bereich:
$6.16
$7.08
52-Wochen-Spanne:
$5.85
$33.68
Upstream Bio Inc Stock (UPB) Company Profile
Firmenname
Upstream Bio Inc
Sektor
Branche
Telefon
781-208-2466
Adresse
890 WINTER STREET, SUITE 200, WALTHAM
Compare UPB vs VRTX, REGN, ARGX, RVMD, ALNY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
UPB
Upstream Bio Inc
|
6.40 | 348.83M | 3.32M | -156.76M | -140.13M | -2.9019 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Upstream Bio Inc Stock (UPB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-27 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2025-12-18 | Eingeleitet | Mizuho | Outperform |
| 2025-11-18 | Eingeleitet | Evercore ISI | Outperform |
| 2025-10-14 | Eingeleitet | Truist | Buy |
| 2024-11-05 | Eingeleitet | JP Morgan | Overweight |
| 2024-11-05 | Eingeleitet | Piper Sandler | Overweight |
| 2024-11-05 | Eingeleitet | TD Cowen | Buy |
| 2024-11-05 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Upstream Bio Inc Aktie (UPB) Neueste Nachrichten
UPB|Upstream Bio Inc|Price:6.410|Chg%:+0.010 - TradingKey
Upstream Bio Inc (UPB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Upstream Bio Inc (UPB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TradingKey - TradingKey
Upstream Bio, Inc. Revenue Breakdown – NASDAQ:UPB - TradingView
Upstream Bio Inc (UPB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Enterprise value to revenue forward of Upstream Bio, Inc. – NASDAQ:UPB - TradingView
Why Did UPB Stock Plunge 40% Today? - Stocktwits
ETFs Investing in Upstream Bio, Inc. Stocks - TradingView
Upstream Bio, Inc. (UPB) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
UPB Q1 2026 Earnings: Narrower Loss Beats Estimates Amid Clinical ProgressEarnings Season Preview - DonanımHaber
Upstream Bio Q1 2026 Earnings: Narrower Loss Beats Expectations, Stock Declines in Pre-Revenue Phase - dars.gov.et
Price to earnings forward of Upstream Bio, Inc. – NASDAQ:UPB - TradingView
Price to book forward of Upstream Bio, Inc. – NASDAQ:UPB - TradingView
UPBUpstream Bio Inc Dividends - Finviz
UPB Q1 2026 Earnings: Narrower-Than-Expected Loss Lifts SharesEarnings Miss Alert - DonanımHaber
Here's Why We're Watching Upstream Bio's (NASDAQ:UPB) Cash Burn Situation - Moomoo
Upstream Bio Inc. (UPB) Q1 2026 Earnings: Narrower-than-Expected Loss Drives Modest Stock DeclineDiluted EPS Report - dars.gov.et
Enterprise value to EBIT forward of Upstream Bio, Inc. – NASDAQ:UPB - TradingView
UpStream Bio(UPB) Stock Options Chain | Quotes & News - Moomoo
Upstream Bio Inc. (UPB) Q1 2026 Earnings: Narrower-than-Expected Loss Drives Positive SentimentGross Profit Margin - dars.gov.et
UPB News | UPSTREAM BIO INC (NASDAQ:UPB) - ChartMill
Upstream Bio, Inc. (UPB) reports Q1 loss, beats revenue estimates - MSN
Upstream Bio, Inc. Actuals & Estimates (NASDAQ:UPB) - TradingView
Upstream Bio, Inc. Actuals & Estimates (BOATS:UPB) - TradingView
UPB Forecast — Price Target — Prediction for 2027 - TradingView
Is Upstream Bio, Inc. (UPB) a Rising Biotech Opportunity After New Analyst Coverage? - Insider Monkey
Enterprise value to EBITDA forward of Upstream Bio, Inc. – NASDAQ:UPB - TradingView
JPMorgan Cuts Upstream Bio Stock Target to Eight Dollars - sekbernews.id
Is Upstream Bio, Inc. (UPB) the Best Low Priced Stocks to Get Rich in 2026? - Yahoo Finance
Upstream Bio (UPB) Consolidates Near Support After Marginal Gains Amid Biotech Sector CautionIV Rank - dars.gov.et
Upstream Bio Inc (UPB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
UPB Technical Analysis & Stock Price Forecast - Intellectia AI
Upstream Bio Inc (UPB) Valuation: PE, PB & Fair Value Analysis - TradingKey
Upstream Bio Inc (UPB) Institutional Confidence - TradingKey
Top Executive Makes Strategic Move With Upstream Bio Stock - TipRanks
Upstream Bio Inc (UPB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Upstream Bio Inc (UPB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Upstream Bio Inc (UPB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Upstream Bio presents positive Phase 2 trial data for verekitug By Investing.com - Investing.com Nigeria
Upstream Bio presents positive Phase 2 trial data for verekitug - Investing.com
Upstream Bio, Inc. unveils Phase 2 VIBRANT trial data showing majority of verekitug recipients achieve key improvements - Traders Union
Upstream Bio Reports Positive Phase 2 Results for Verekitug in Chronic Rhinosinusitis with Nasal Polyps, Achieving Clinically Meaningful Improvements in Key Symptoms - Quiver Quantitative
Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements ... - Caledonian Record
Upstream Bio Presents New Responder Analyses Demonstrating - GlobeNewswire
Upstream Bio Inc. (UPB) Falls 4.39% as Shares Test Key Support LevelGamma Exposure - newsline.com
UPB Q1 2026 Earnings: Narrower-than-Expected Loss as Clinical Progress ContinuesEstimate Accuracy - newsline.com
Finanzdaten der Upstream Bio Inc-Aktie (UPB)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.97%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):